文献速递慢性肾脏病

血浆钙卫蛋白水平与新发慢性肾脏病相关的前瞻性研究

A Prospective Study of the Association Between Plasma Calprotectin Levels and New-Onset CKD in the General Population.
PubMed 文献 · Kidney Int Rep · 2024-02-16

在荷兰PREVEND前瞻性人群队列中,纳入基线无CKD的4662人,中位随访8.3年,467人发生新发CKD。基线血浆钙卫蛋白每翻倍与新发CKD风险升高相关(HR 1.28,95%CI 1.14-1.44,P<0.001),校正混杂因素后仍显著(HR 1.14,95%CI 1.01-1.29,P=0.034),但进一步校正hs-CRP后关联减弱(HR 1.05,95%CI 0.91-1.21,P=0.494)。

要点

  • 血浆钙卫蛋白每翻倍与新发CKD风险独立相关(HR 1.14,95%CI 1.01-1.29)。
  • 校正hs-CRP后关联不再显著,提示炎症通路可能介导该关联。
  • 钙卫蛋白与尿白蛋白排泄>30 mg/24h的关联显著(HR 1.17,95%CI 1.02-1.34)。

核心结论

  • 在一般人群中,较高的血浆钙卫蛋白水平与新发CKD风险增加相关。
  • 该关联在校正hs-CRP后减弱,提示部分由系统性炎症解释。
  • 钙卫蛋白与新发CKD的关联在以尿白蛋白排泄定义的结局中更明显。

研究设计与样本

  • 前瞻性人群队列研究(PREVEND研究),纳入基线无CKD的4662名个体。
  • 基线血浆钙卫蛋白在-80°C储存样本中检测。
  • 新发CKD定义为eGFR<60 ml/min per 1.73 m2、尿白蛋白排泄>30 mg/24h或两者兼有。

主要发现

  • 基线血浆钙卫蛋白中位数(四分位距)为0.49(0.35-0.68)mg/l。
  • 基线eGFR中位数(四分位距)为95.9(85.0-105.7)ml/min per 1.73 m2。
  • 中位随访8.3(7.8-8.9)年,467名参与者发生新发CKD。
  • 基线血浆钙卫蛋白每翻倍与新发CKD风险相关(HR 1.28,95%CI 1.14-1.44,P<0.001)。
  • 校正潜在混杂因素后关联仍显著(HR 1.14,95%CI 1.01-1.29,P=0.034),但校正hs-CRP后不显著(HR 1.05,95%CI 0.91-1.21,P=0.494)。

临床怎么用

  • 血浆钙卫蛋白可作为一般人群新发CKD风险的炎症相关生物标志物进行进一步评估。
  • 解读钙卫蛋白与CKD风险关联时需考虑hs-CRP水平,因其可能介导或混杂该关联。
  • 钙卫蛋白与白蛋白尿型CKD的关联更强,提示对早期肾小球损伤的潜在价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Systemic inflammation has been associated with chronic kidney disease (CKD). In this study, we aimed to investigate a potential association between the plasma biomarker of inflammation calprotectin and new-onset CKD in a population-based cohort study. METHODS: Individuals without CKD at baseline (n = 4662) who participated in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) prospective population-based cohort study in the Netherlands were included. Baseline plasma calprotectin levels were assessed in samples that had been stored at -80 °C. Occurrence of new-onset CKD was defined as a composite outcome of an estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m2, urinary albumin excretion (UAE) >30 mg/24h, or both. RESULTS: Baseline median (interquartile range) plasma calprotectin levels were 0.49 (0.35-0.68) mg/l and baseline median eGFR was 95.9 (interquartile range: 85.0-105.7) ml/min per 1.73 m2. After median follow-up of 8.3 (7.8-8.9) years, 467 participants developed new-onset CKD. Baseline plasma calprotectin levels were significantly associated with an increased risk of new-onset CKD (hazard ratio [HR] per doubling 1.28 [95% confidence interval, CI: 1.14-1.44], P < 0.001), independent of potentially confounding factors (HR 1.14 [95% CI: 1.01-1.29], P = 0.034), except for baseline high-sensitive C-reactive protein (hs-CRP) (HR 1.05 [0.91-1.21], P = 0.494). In secondary analyses, the association between plasma calprotectin and occurrence of UAE >30 mg/24h remained significant (HR 1.17 [1.02-1.34], P = 0.027), but not significantly so for the incidence of eGFR <60 ml/min per 1.73 m2 as individual outcome (HR 1.15 [0.92-1.43], P = 0.218). CONCLUSION: Higher plasma calprotectin levels are associated with an increased risk of developing CKD in the general population. This association is mitigated after adjustment for hs-CRP, and more pronounced with new-onset CKD defined by UAE.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Bourgonje AR, Bourgonje MF, la Bastide-van Gemert S, et al. A Prospective Study of the Association Between Plasma Calprotectin Levels and New-Onset CKD in the General Population. Kidney Int Rep. 2024. PMID: 38707832. doi:10.1016/j.ekir.2024.02.1392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。